Stellanova Therapeutics rakes in $15.5m Series A

Stellanova Therapeutics Inc, a biotechnology company advancing cancer therapies targeting the tumor microenvironment, has secured $15.5 million in Series A financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this